Irrefutable evidence for the use of docetaxel in newly diagnosed metastatic prostate cancer: results from the STAMPEDE and CHAARTED trials

по van Soest, Robert J., de Wit, Ronald
Опубликовано в: BMC Med (2015)

A bypass mechanism of abiraterone‐resistant prostate cancer: Accumulating CYP17A1 substrates activate androgen receptor signaling

по Moll, Jan M., Kumagai, Jinpei, van Royen, Martin E., Teubel, Wilma J., van Soest, Robert J., French, Pim J., Homma, Yukio, Jenster, Guido, de Wit, Ronald, van Weerden, Wytske M.
Опубликовано в: Prostate (2019)

Prognostic factors in men with metastatic castration-resistant prostate cancer treated with cabazitaxel

по Belderbos, Bodine P.S., de Wit, Ronald, Hoop, Esther Oomen-de, Nieuweboer, Annemieke, Hamberg, Paul, van Alphen, Robbert J., Bergman, André, van der Meer, Nelly, Bins, Sander, Mathijssen, Ron H.J., van Soest, Robert J.
Опубликовано в: Oncotarget (2017)

Loss of SLCO1B3 drives taxane resistance in prostate cancer

по de Morrée, Ellen S, Böttcher, René, van Soest, Robert J, Aghai, Ashraf, de Ridder, Corrina M, Gibson, Alice A, Mathijssen, Ron HJ, Burger, Herman, Wiemer, Erik AC, Sparreboom, Alex, de Wit, Ronald, van Weerden, Wytske M
Опубликовано в: Br J Cancer (2016)

Effects of prednisone on docetaxel pharmacokinetics in men with metastatic prostate cancer: A randomized drug–drug interaction study

по Belderbos, Bodine P.S., Hussaarts, Koen G.A.M., van Harten, Leonie J., Oomen‐de Hoop, Esther, de Bruijn, Peter, Hamberg, Paul, van Alphen, Robbert J., Haberkorn, Brigitte C.M., Lolkema, Martijn P., de Wit, Ronald, van Soest, Robert J., Mathijssen, Ron H.J.
Опубликовано в: Br J Clin Pharmacol (2019)